Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Greg Schreiner, the pianist, narrator and producer of Hollywood Revisited, will present “Out of the Closet and Into the Day — ...

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rockwall ISD sixth grade SAGE students recently participated in a “Pathways to Success” field trip where they had the ...

From consumer to tech, here's a list of key deals reported this week: Molson Coors Beverage (TAP) has agreed to acquire an 8.5% stake in Fevertree Drinks, becom ...

In its 10th year, SAGE opened its "My Hometown" photography show to anyone with a phone camera, stipulating any photo ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...